Generics Bulletin is not in the business of rumors but with Sandoz the rumors were often too loud and vocal to ignore. After replacing Joe Jimenez as Novartis CEO in February 2018, Vas Narasimhan for some time quashed talk that Sandoz would be separated from its parent company, although it was clear that the wheels were already in motion.
The Separation Of Sandoz, A Story Years In The Making
Proposed Spin From Novartis Set For 4 October, Following Years Of Conjecture
Novartis’ shareholders last month voted yes on the proposal to separate Sandoz into a standalone generics and biosimilars firm. On the eve of the spin-off, Generics Bulletin looks back at a deal that was seemingly destined to happen sooner rather than later.
More from Strategy
More from Business
• By
Generics Bulletin previews the most noteworthy and anticipated events for May 2025.
• By
Sandoz has struck a deal worth up to $301m with Henlius giving it rights to a proposed ipilimumab biosimilar to Yervoy in countries across the world.
• By
Reflecting increased regulatory pressure and a wider drive towards the reshoring of pharmaceutical manufacturing to the US, Speranza has launched a new generics business called Lotus Therapeutics.